<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897738</url>
  </required_header>
  <id_info>
    <org_study_id>AmberenSmartB-2019</org_study_id>
    <nct_id>NCT03897738</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Effectiveness and Safety of Amberen and Smart B in Perimenopausal Women.</brief_title>
  <official_title>Clinical Evaluation of Effectiveness and Safety of Combined Use of Dietary Supplements Amberen and Smart B in Women With Climacteric Syndrome in Perimenopause</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I.M. Sechenov First Moscow State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I.M. Sechenov First Moscow State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate effectiveness and safety of combined use of dietary supplements Amberen and Smart
      B in women with a typical (without complications) form of climacteric syndrome, with mild to
      moderate symptoms in perimenopause.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To evaluate effectiveness of combined use of dietary supplements Amberen and Smart B in
           women vasomotor, psychosomatic, psychological and other climacteric symptoms in
           perimenopause.

        2. To evaluate safety of combined use of dietary supplements Amberen and Smart B in women
           with vasomotor, psychosomatic, psychological and other climacteric symptoms in
           perimenopause.

        3. To develop recommendations for combined use of dietary supplements Amberen and Smart B
           for women with vasomotor, psychosomatic, psychological and other climacteric symptoms in
           perimenopause.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2019</start_date>
  <completion_date type="Actual">February 18, 2020</completion_date>
  <primary_completion_date type="Actual">February 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;Heart beating quickly and strongly&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 1 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Feeling tense or nervous&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 2 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Difficulty sleeping&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 3 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Increased Excitability&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 4 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Panic attacks&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 5 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Difficulty concentrating&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 6 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Feeling tired or lacking energy&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 7 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Loss of interest in most things&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 8 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Feeling of sadness or depression&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 9 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Crying spells&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 10 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Irritability&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 11 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Feeling dizzy or faint&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 12 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Pressure or tightness in head or body&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 13 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Parts of body feeling numb or tingling&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 14 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Headaches&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 15 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Muscle or joint pains&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 16 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Loss of feeling in hands or feet&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 17 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Breathing difficulties&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 18 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Hot flushes&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 19 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Night sweats&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 days and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 20 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Loss of interest in sex&quot; symptom (Greene Climacteric Scale)</measure>
    <time_frame>90 and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. This is question 21 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = &quot;not at all&quot;; 2 = &quot;a little bit&quot;; 3 = &quot;quite a bit&quot;; 4 = &quot;extremely&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood plasma estradiol levels, pg/ml</measure>
    <time_frame>90 and 180 days</time_frame>
    <description>Statistically significant changes in the levels, compared between arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory (State anxiety sub-scale)</measure>
    <time_frame>90 and 180 days</time_frame>
    <description>Statistically significant change of the score in corresponding sub-scale. Scores range from 20 to 80, with higher scores correlating with greater anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory (Trait anxiety sub-scale)</measure>
    <time_frame>90 and 180 days</time_frame>
    <description>Statistically significant change of the score in corresponding sub-scale. Scores range from 20 to 80, with higher scores correlating with greater anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory (Actual anxiety, combination of state and trait sub-scales )</measure>
    <time_frame>90 and 180 days</time_frame>
    <description>Statistically significant change of the score in corresponding sub-scale. Scores range from 20 to 80, with higher scores correlating with greater anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Well-being sub-score (Russian well-being, activity and mood questionnaire)</measure>
    <time_frame>90 and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. The sub-scale score varies from 10 to 70 points, with the higher score corresponding to more positive self-evaluation of well-being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity sub-score (Russian well-being, activity and mood questionnaire)</measure>
    <time_frame>90 and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. The sub-scale score varies from 10 to 70 points, with the higher score corresponding to more positive self-evaluation of one's activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood sub-score (Russian well-being, activity and mood questionnaire)</measure>
    <time_frame>90 and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. The sub-scale score varies from 10 to 70 points, with the higher score corresponding to more positive self-evaluation of one's mood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety sub-score (measured by Hospital Anxiety and Depression Scale)</measure>
    <time_frame>90 and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. The scores range from 0 to 21.
0-7 = Normal 8-10 = Borderline abnormal 11-21 = Abnormal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression sub-score (measured by Hospital Anxiety and Depression Scale)</measure>
    <time_frame>90 and 180 days</time_frame>
    <description>Statistically significant change in designated symptom severity, compared between arms. The scores range from 0 to 21.
0-7 = Normal 8-10 = Borderline abnormal 11-21 = Abnormal</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Perimenopause, Climacteric Syndrome</condition>
  <arm_group>
    <arm_group_label>Amberen and Smart B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
Placebo capsules are identical to Amberen and Smart B capsules.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Amberen</intervention_name>
    <description>Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.</description>
    <arm_group_label>Amberen and Smart B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Smart B</intervention_name>
    <description>Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.</description>
    <arm_group_label>Amberen and Smart B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules are identical to Amberen and Smart B capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects, 50 years of age or younger;

               -  Subjects in the second phase of menopausal transition as per STRAW 10+ i.e.
                  interval of amenorrhea 60 days or more (with regular menstrual cycle during
                  earlier reproductive stages).

               -  Subjects with diagnosis of mild to moderate climacteric syndrome;

               -  Recent (up to 12 months prior to study enrollment) breast exam results, including
                  mammogram, that rule out malignancies;

               -  Recent (up to 3 years prior to study enrollment) cytological screening that rules
                  out vaginal cervix malignancies.

               -  Ability to read and understand informed consent form for the study's
                  participation;

               -  Ability to adhere to the conditions of the study.

        Exclusion Criteria:

          -  • Postmenopause, including surgical menopause.

               -  Presence of hormone-dependent cancers;

               -  Presence of other cancers, not in full remission with no recurrence for 5 years
                  or more;

               -  Planned hospitalization in the next 6 months;

               -  Presence of hormonally-active extragenital endocrine diseases (diabetes; diseases
                  of thyroid, adrenal, pituitary) that require prolonged or life-long therapies

               -  Surgical interventions on sex organs or breasts, 1 year or less prior to the
                  screening;

               -  Gynecological conditions that may require hormonal therapies or surgeries
                  (uterine myoma, endometriosis, endometrial hyperplasia etc.);

               -  Currently undergoing or planning to utilize assisted reproductive technologies;

               -  Any abdominal surgeries within less than 3 months prior to the screening;

               -  HRT including MHRT or hormonal contraceptives - current or within less than 3
                  months prior to the screening;

               -  Psychiatric conditions;

               -  Patients taking any other dietary supplements that can affect climacteric
                  syndrome within the last month before enrolling in the trial;

               -  High risk of non-compliance.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sechenov First Moscow Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>I.M. Sechenov First Moscow State Medical University</investigator_affiliation>
    <investigator_full_name>Kuznetsova Irina</investigator_full_name>
    <investigator_title>Chief Researcher, Scientific Research Centre, Women's Health Scientific Research Department, I.M. Sechenov First Moscow State Medical University, University hospital #2, Obstetrics and Gynecology clinic.</investigator_title>
  </responsible_party>
  <keyword>succinate</keyword>
  <keyword>B complex vitamins</keyword>
  <keyword>perimenopause</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

